The company has a significant R&D arm in Ireland with numbers employed in R&D last year increasing from 224 to 270. Last year ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...